A B S T R A C T The role of glucagon in the metabolic adaptation to prolonged fasting in man has been examined. Plasma immunoreactive glucagon was determined during 6-wk fasts and during infusion of exogenous glucagon using an assay which minimized nonpancreatic immunoreactivity.
INTRODUCTION
Although glucagon is essential to metabolic homeostasis in some species (1, 2), a physiologic role in man has not Received for publication 11 June 1970 and in revised form 27 July 1970. been defined. Glucagon secretion is responsive to induced hypoglycemia (3) and to infusion or ingestion of large loads of amino acids (4), but these are not standard challenges within the physiologic setting of alternating meal consumption and fasting. Since man maintains his blood glucose concentration mainly by gluconeogenesis (5) , the glycogenolytic effect of glucagon may not be a primary function, except in "emergency" situations. Unger and colleagues have suggested that the relative levels of insulin and glucagon are important in fasting and after amino acid challenge. In fasting they demonstrated elevated plasma levels of immunoreactive glucagon in the presence of lowered insulin levels and have suggested a synergistic effect on hepatic glucose release (6) . In the latter situation during protein or amino acid challenge, they have proposed that the parallel increases of glucagon with increasing insulin levels prevent the hypoglycemia that would otherwise occur if insulin levels alone were to rise (7) .
It has been shown that man, when fasted, reaches a near steady state with respect to protein, fat, and carbohydrate metabolism by 3 wk (8) . Gluconeogenesis from protein, though initially increased, diminishes to a plateau by this time, as the adaptation of brain to ketone body oxidation reduces the glucose requirement of the body. Any induced hormonal alteration at such a time might be expected to influence this metabolic adjustment in a manner which provides insight into the relative importance of the physiological effects of the hormone to fuel homeostasis. Furthermore, the availability of hormonal assays now permits quantification of the levels of hormone achieved during its administration and permits correlation with known physiological levels. Presently available immuno-and bioassays demonstrate that pancreatic glucagon circulates in extremely low concentrations (7, 9) . Metabolic responses in most previous studies have therefore been a result of pharmacologic per cent disappearance per minute (after glucose, 0.5 g/kg).
levels of the hormone. The current study was designed to quantify the in vivo metabolic effects of glucagon when given by constant infusion in more physiologic dosage in fasting man. In addition, levels of endogenous glucagon throughout periods of prolonged fasting have been determined.
METHODS
Subjects. 15 obese subjects were admitted to The Clinical Center of the Peter Bent Brigham Hospital (Table I) ; each had been carefully screened prior to fasting to assure that no endocrine abnormality was present. None had a history, signs, or symptoms of cardiac, renal, or hepatic disease or gout. The screening tests employed have been described (8) . The patients were informed of the nature, purpose, and possible risks involved in fasting and in the infusion procedures, and each had volunteered to undergo prolonged fasting as a therapeutic measure.
The patients were not losing weight prior to admission, and for at least 3 days before fasting they received a 2500 calorie diet containing 300 g of carbohydrate, 100 g of protein, and 85 g of fat. Daily intake during fasting (35) (36) (37) (38) (39) (40) (41) (42) (43) days) consisted of a minimum of 2000 ml of water, 17 mEq of NaCl, one multivitamin tablet (Theragran; E. R. Squibb & Sons, New York), and, in most patients, 17 mEq of KCl. These medications contained no appreciable calories. No dietetic food or beverage or other intake was permitted.
Blood and urine collection and analyses. Blood was drawn between 8 and 9 a.m. from an antecubital vein without stasis with patients recumbent for at least 90 min. It was immediately distributed into tubes for the analyses described. (a) Oxalate-fluoride tubes were used for triplicate blood glucose analyses by the Technicon AutoAnalyzer ferricyanide procedure (Technicon Corporation, Tarrytown, N. Y.). (b) Tubes containing lithium-heparin were employed for analysis of free amino acids on plasma deproteinized with sulfosalicylic acid, as previously described (10), using the automated ion-exchange chromatographic technique on a Beckman 120C amino acid analyzer (Beckman Instruments Inc., Palo Alto, Calif.) modified to provide simultaneous recording from two columns. Glutamine and glutamate are not reliably quantified in plasma by this method and where reported were determined by specific enzymatic assay (11) . Filtrates (13) .
Statistical analyses were performed according to Snedecor (14) . 
RESULTS
The mean morning values of blood glucose and plasma immunoreactive glucagon and serum insulin at day 0 (postabsorptive) and at intervals throughout a prolonged period of fasting in seven subjects are presented in Fig.  1 . There was a significant rise in glucagon from the postabsorptive mean of 73 1AIzg/ml (sEM ±4.7) to a maximum on day 3 of 144 ±15.7 u'g/ml (P < 0.01). This rise was followed by a gradual return toward prefast levels, but the values remained-significantly elevated at day 5, 14, and 42. This early rise is identical with that previously reported using the same immunoassay (6) in nonobese subjects fasted 4 days. Also similar is the fall in insulin levels with fasting, a well-recognized phenomenon which is clearly associated with falling glucose concentrations. 'Thus the hormonal milieu of prolonged fasting is characterized by lowered -insulin levels, elevated or normal immunoreactive glucagon levels', and low blood glucose. Table II Table  III , and again no significant change in concentration of the individual amino acids was noted.
The responses of circulating substrates and hormones to glucagon. infusion at two dose-levels (10 -mg/24 hr and 1 mg/24 hr) are shown in Table IV and Fig. 2 . Blood glucose rose with infusion of both doses of glucagon and was significant (P < 0.05, paired t test) at most sampling intervals. The higher dose infusion pro- duced higher glucose and insulin levels, but there was much interindividual variation. Glucagon levels in excess of 2000 M/g/ml were achieved and maintained throughout the infusions of 10 mg/24 hr. In the 1 mg/24 hr infusions, the plasma concentrations were still above the peripheral venous levels of glucagon observed by stimulation of endogenous secretion (6) , but within the range measured in portal venous plasma in animals (15) and in peripheral venous plasma in man in diabetic acidosis (12) .
Serum growth hormone levels rose in both groups to significantly higher than preinfusion levels at 16 hr (P <0.05, paired t test). Again the absolute values were higher with the 10 mg/24 hr dose, but interpretation of these is complicated by the fact that this group comprised two females and two males, whereas the five subjects in the 1 mg/24 hr dose group were all males (although zero time values were not significantly different).
Mean plasma free fatty acids underwent a slight but insignificant fall in the first 24 hr, followed by a secondary rise in the next 24 hr which, though greater in the higher dose group, reached significantly greater than baseline values only in the 1 mg/24 hr group at 32 hr (P <0.05, paired t test). A similar pattern was observel for blood P-hydroxybutyrate in the 10 mg/24 hr studies, but a progressive decline occurred in the lower dose group, which was significant compared with the control value at 24 hr (P < 0.05, paired t test). Blood acetoacetate and glycerol did not exhibit significant changes from preinfusion concentrations.
Urinary ketone acid excretion is shown in Table V . In both groups an increase in ketone excretion was observed, most marked in the 10 mg/24 hr group. This increased excretion corresponded to the diminution in blood P-hydroxybutyrate on the 1st day and the increase on the 2nd day of infusion in the higher dose group. But in the lower-dose group, the increase in urinary excretion was associated with a progressive decrease in blood levels.
The 24 hr urinary total nitrogen excretion is shown in Fig. 3 (8) . Day 1 of the infusion was, in general, several days later in the fast for the group receiving 10 mg of glucagon per 24 hr, probably in part accounting for the somewhat lower urea nitrogen excretion for this group in the perinfusion period.
The effect noted in both groups was an increase in urea nitrogen excretion beginning on the 1st day and becoming significant on the 2nd day of infusion. Levels returned to preinfusion values promptly in the lower dose group, but they remained elevated for several days after the termination of the 10 mg/24 hr infusions. No change in ammonia nitrogen excretion occurred. This is consistent with the failure of glucagon infusion to have altered the blood acid-base equilibrium typical of prolonged fasting (compensated metabolic acidosis).
Concurrent with the increase in urea nitrogen excretion, the plasma concentrations of individual free amino acids showed striking changes (Table VI) . All amino acids measured during the 10 mg/24 hr infusions diminished significantly, and only taurine and phenylalanine failed to diminish during the 1 mg/24 hr infusions. In every other instance, the response to the lower dose infusions was similar to but smaller in magnitude than the response to the higher dose. Apart from taurine and phenvlalanine in the 1 mg/24 hr infusions, three general patterns of response were observed. Two of these are demonstrated by representative amino acids in Fig. 4 . The first group is represented by glycine and is characterized by either a progressive decline in plasma concentration or a decline to a plateau. This group includes serine, proline, citrulline, alanine, a-aminobutyric acid, half cystine, ornithine, and arginine. The second group, represented by leucine, showed a transient decrease followed by a return to levels not significantly different from preinfusion by 24 hr. Included were valine, leucine, and isoleucine (1 mg/24 hr only). Methionine similarly decreased transiently but remained significantly lower until after the 24-hr interval. A third response, that of lysine and histidine (in the 10 mg/24 hr studies), was a decrease, a recovery toward preinfusion at 24 hr, then a subsequent decrease.
The zero time values in the two groups were comparable and in both instances showed the pattern previously published for prolonged-fasted subjects (10) .
The responses of the five subjects receiving 0.1 m-g/24 hr are shown in Fig. 5 . No change in blood glucose or insulin occurred during the significant elevation of immunoreactive glucagon from the preinfusion mean of 102 ±3 to a mean of 143-180 A,*g/ml. Similarly, plasmafree fatty acids and blood ketones did not change. Growth hormone was not determined. Urinary P-hydroxybutyrate ±SEM for five prolonged-fasted subjects and show the probability that concentrations during infusion do not differ from zero time (paired t test). Zero time value'of glucose 'and insulin is the mean of the 3 days preceding in-fusioti.
increased significantly during the first 24 hr' (P < 0.01) but returned to baseline thereafter. Acetoacetate excre-' tion did not change significantly. Urine' nitrogen responses are shown in Fig. 6 , and these contrast with the higher dose groups (Fig. 3) , in that a' significant fall in urea nitrogen excretion occurred. Whether this fall-is' greater than would have occurred without intervention cannot be determined. Individual plasma amino acids whose levels' fell significantly (P <0.05, paired t test) during these infusions are shown in Fig. 7 . Particularly noteworthy are the decreases in threonine, serine, and glycine, vhich are elevated with prolonged fasting and which show a postinfusion rebound. There was no change in the concentration of the remaining measured amino acids.
DISCUSSION
Circadian rhythm of substrate and insulin concentrations. The studies performed on day 28 confirm-thatthe near steady-state metabolic adaptation of prolonged fasting obtains without significant variation in the parameters examined in relation to time of day. Thus any changes demonstrated during glucagon infusion may be attributed solely to the effects of the hormone.
Though circadian 'changes in blood glucose and serum insulin unrelated to meal taking in the fed state have been suggested (16, 17) , such'changes did not occur during 'prolonged fasting. Similarly, the measured parameters reflecting fat mobilization (free fatty acid and glycerol) and hepatic oxidation of fatty acid (the levels, of ketone acids) do --not show variations at the times of the day studied. These observations suggest that the glucoregulatory and fat-mobilizing mechanisms which result in the fasting adaptation are not regulated by.
hormones-whose secretion may show circadian change, or change related 'to intermittent activity -(though -the' subjects were recumbent for 90 min prior to-blood' sampling). (19) that the previously observed circadian amino acid rhythms are at least partly, if not entirely, patterned by meal taking and its induced hormonal responses.
Immunoreactive glucagon levels in prolonged fasting. The present findings confirm and amplify those of Aguilar-Parada, Eisentraut and Unger, who have recently demonstrated a 50% rise in glucagon levels in 3-and 4-day fasts in normal weight volunteers (6). The peak rise of 100% on day 3 of the present study thus corresponds closely to their observations. A similar early elevation of glucagon had been demonstrated previously (3, 20) , but its interpretation was questioned because of the lack of antisera specific for pancreatic glucagon. They assay procedure used in the present study has been modified to exclude nonpancreatic glucagon-like immunoreactivity (12) .
This early rise in plasma glucagon corresponds to a transient period of accelerated hepatic gluconeogenesis, as evidenced by urinary urea nitrogen and by enhanced splanchnic amino acid extraction. Indeed, an increase in the fractional splanchnic extraction of alanine, the principal gluconeogenic amino acid, from 43% postabsorptively to 71% on day 3 has been reported recently from this laboratory (10) . Fractional alanine extraction returned to 53% at 5-6 wk of fasting, a pattern which correlates with the fall in glucagon toward postabsorptive levels beyond day 3. Thus, a synergism of the decrease in circulating insulin and increase in glucagon may be viewed as the cause of stimulated hepatic gluconeogenic mechanisms early in fasting. Although the absolute level of glucagon later falls, the low insulin levels result in an increased ratio of glucagon to insulin, which persists and may be responsible for determining the proportion of amino acid extracted by the liver in prolonged fasting. The work of Mackrell and Sokal (21) in the isolated perfused rat liver has confirmed the importance of the relative concentrations of these hormones in regulating hepatic metabolism. Furthermore, Lewis, Exton, Ho, and Park (22) /g/ml) . Thus the increment in peripheral venous glucagon observed in fasting must reflect an increment in the portal venous concentration well within the range expected to be regulatory.
An additional effect of the early peak of glucagon may be to produce that amount of hepatic glycogenolysis which contributes in a quantitatively minor fashion to the glucose made available early in fasting in man (5) . Similarly, a synergism with declining insulin levels on lipolysis may be another consequence of both the early absolute rise and sustained relative hyperglucagonemia.
The progressive diminution of gluconeogenesis from protein (8) has been shown to reside at the muscle (the body's principal protein store), which determines the amount of amino acid substrate made available to liver. The amount of amino acid released during prolonged fasting is markedly curtailed (24) . Whether glucagon may directly influence this muscle efflux is currently being studied. That the initial glucagon rise might be related to the decrease in blood glucose has been suggested by several investigators who have proposed glucagon to be the primary hormone of chronic "glucose need" as well as of acute hypoglycemia. This may be an important regulator of glucagon secretion in other situations, but it cannot explain the secondary decline in glucagon levels, which occurs during a period of constant, though decreased, blood glucose concentration.
The control of the biphasic pattern of glucagon levels is thus unexplained. A relation exists, however, between the pattern of plasma branched-chain amino acid levels and glucagon, since a transient elevation in the former also occurs early in fasting (10) . It is now well recognized that many amino acids are potent stimulators of glucagon as well as of insulin secretion (15) . Felig, Marliss, and Cahill (25) recently proposed that endogenous levels of amino acids, particularly the branchedchain amino acids (valine, leucine, and isoleucine), may exert a tonic influence on beta cell secretory activity, secondary in sensitivity to the glucose levels. Thus, the rise in these amino acids seen early in fasting has been interpreted to be the result of declining blood glucose and insulin levels and a diminution in the known effect of insulin of inhibiting muscle release of these amino acids (26) . It is possible that the early hyperglucagonemia may be a reflection of the increased levels of valine or isoleucine, and the secondary decline related to the decrease in the same amino acids. The possibility of enhanced glucagon responsiveness to endogenous levels of amino acids is also raised by the data of AguilarParada and colleagues in which glucagon increments in response to arginine infusion were greater in subjects fasted 3 days than in the same subjects in the postabsorptive state (6) .
Glucagon infusions in prolonged fasting. (29) and in vivo in other species (30) was not evident in these studies, in that plasma-free fatty acid and blood glycerol concentrations did not rise significantly.
to levels not different from zero time amino acids shown except alanine and Glucagon has recently been reported -to affect concentrations of individual plasma amino acids in man (31) and animals (32) . The present findings confirm the observed effect of a decrease in levels of most amino acids and of previous studies in which total amino acids (as alpha-amino nitrogen) were measured (33) . These investigations uniformly employed large doses of glucagon.
That a primary site of the amino acid lowering effect is the liver is suggested by the data referred to above, indicating increased urea nitrogen excretion in the studies with higher glucagon doses. Since no change in the "unmeasured" urine nitrogen component was observed, it is unlikely that a substantial increase in renal amino acid excretion could account for the hypoaminoacidemia. Studies by Kibler, Taylor, and Meyers in man (34) and by Shoemaker and Van Itallie in dogs (35) have shown increased splanchnic extraction of alphaamino nitrogen after glucagon. These in vivo experiments do not account for possible heterogeneity of hepatic response to glucagon with respect to individual amino acids, nor to the induced insulin response exert-ing a peripheral effect (26) in reducing circulating amino acid levels. That the former is important has recently been demonstrated by Mallette, Exton, and Park (36) with physiological glucagon doses in isolated perfused livers of fed rats. Indeed, the following four different patterns of response were shown: (a) uptake of histidine, the only amino acid with resting uptake or output, was unchanged by glucagon; (b) uptake of glycine, alanine, phenylalanine, arginine, and lysine was stimulated; (c) output of leucine, isoleucine, and valine resulted; (d) tyrosine, methionine, and tryptophan handling did not change. Furthermore, the alterations in extracellular and intracellular concentration of free amino acids suggested that the observed response resulted from one or a combination of the following mechanisms: (a) increased intracellular utilization, for example, for gluconeogenesis, (b) stimulation of inward transport, and (c) intracellular production, as from proteolysis.
The most striking difference between these findings in vitro and those of the present study is that, with no important exception, all circulating amino acids measured decreased in concentration at least transiently. This may be accounted for by one or more of three possibilities: (a) species differences, (b) difference in the dose levels administered, or (c) presence of other responses in vivo which might obscure a similar effect in hepatic proteolysis and hepatic production of certain amino acids (36) .
Levels of glucagon in the portal vein in the postabsorptive state are probably 500-800 ,Ag/ml, as estimated from values determined in prancreaticoduodenal veins of dogs (15) , which have similar peripheral vein concentrations to those in man. Thus, in order that peripheral vein levels double (as observed in early fasting), it would be anticipated that portal vein concentrations would increase at least twofold. The current studies employing 1 mg/24 hr showed hyperglycemia and stimulated gluconeogenesis with peripheral levels of glucagon of 700-1400 uiug/ml. This suggests that the observed elevations in endogenous peripheral glucagon levels early in fasting reflect levels in portal blood which would be expected to stimulate hepatic gluconeogenesis, further confirming an important regulatory role in fasting.
The studies employing 0.1 mg of glucagon per 24 hr demonstrate the exquisite sensitivity of the amino acid lowering effect. Kaminsky and colleagues (37) , infusing 1.5 times this amount into postabsorptive man, recently showed highly significant increases in plasma cyclic 3',5'-adenosine monophosphate concentration, further evidence of an effect at low levels. In light of the high concentrations of glucagon to which the liver is always exposed as compared with the periphery, the increment in the 0.1 mg/24 hr infusions is proportionally greater at the periphery (75%) than at the liver (probably less than 20%). This, in addition to the absence of increased urea excretion, suggests that an extrahepatic site may contribute to the hypoaminoacidemia. Whatever the locus of this effect, its demonstration at physiologic levels clearly implicates glucagon as an important regulator of amino acid metabolism.
Finally, the levels of glucagon obtained with the two lower rates of infusion confirm the accuracy of the glucagon determinations. Distribution of the infused hormone into the extracellular fluid with an estimated half-time of disappearance of 10-15 min would be expected to induce the magnitude of rise observed. The endogenous levels reported are thus validated as bona fide estimates of pancreatic glucagon.
